Market cap still sub $50 AUD million, and we now have drug...

Market cap still sub $50 AUD million, and we now have drug hitting arms in what is hopefully a fast-tracked registration trial. Fair value, when you look at other biotechs in the same type of position is anywhere from 3 to 10 bags from where we are now. But this market is fickle. There have been recent companies that have doubled their value in short time with the right announcements. Others have gone backwards.

At this end of the market buying the share is the easy bit. Knowing what to do with them once you buy them is the hard part. Look at OPT and IMU as examples. Both had good runs, overshot and pulled back. This is normal. Its important not to get too greedy. Take some profit on the way. But make sure you keep some!

Still a bit to go, but each day we are getting closer to some results. Lets hope they are goodies. We just need to replicate the last trial. As this is being targeted against a biomarker, we can roll those results towards other inflammatory diseases with the same biomarker. This could become the drug that keeps on giving.